Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: astaxanthin prodrugs - Cardax Pharmaceuticals

Drug Profile

Research programme: astaxanthin prodrugs - Cardax Pharmaceuticals

Alternative Names: CDX-085; CDX-101; Heptax; XanCor

Latest Information Update: 20 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardax Pharmaceuticals
  • Class Anti-inflammatories; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antirheumatics; Antithrombotics; Hepatoprotectants; Nootropics; Vascular disorder therapies; Xanthophylls
  • Mechanism of Action Antioxidants; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypertriglyceridaemia; Liver disorders; Metabolic syndrome; Osteoarthritis; Thrombosis
  • Research Atherosclerosis; Cognition disorders; Dyslipidaemias; Inflammation; Type 2 diabetes mellitus
  • No development reported Rheumatoid arthritis

Most Recent Events

  • 15 Aug 2019 Cardax Pharmaceuticals plans for IND enabling studies for CDX-101
  • 14 Aug 2019 Cardax Pharmaceuticals plans a phase I trial for CDX 101
  • 17 May 2019 Early research in Dyslipidaemias in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top